cltc certification,
cltc certification, with http://www.medical-mailings.com

cltc certification,

medical mailings

News for 02-Feb-24

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet Asthma General
Bronchodilators (Drug Class)

Source: MedicineNet Diabetes General
Insulin Prices Skyrocket, Putting Many Diabetics in a Bind

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet Asthma General
Cured Meats Could Aggravate Asthma, Study Suggests

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet Asthma General
Churg-Strauss Syndrome

Source: MedicineNet Asthma General
Asthma Medications

Source: MedicineNet Asthma General
Clean Home May Help Keep Kids' Asthma in Check

Search the Web
daily medical news
cltc certification,
laparoscopic instruments
prostate cancer
online reference resources,
md jobs
patient
obgyn
gynecological ultrasound
doctor who

The Best cltc certification, website

All the cltc certification, information you need to know about is right here. Presented and researched by http://www.medical-mailings.com. We've searched the information super highway far and wide to provide you with the best cltc certification, site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
cltc certification,.

cltc certification,

medical mailings, email campaigns
Need information on Medical Mailings? Our links will provide you with information on all type of type of Medical Mailings for Physicians over the internet including email and snail mail. For conferencing services to go with your email campagin go to Meetings on the Net - http://www.meetingsonthenet.com
medical mailings, email campaigns

Being assured you're receiving value for money is crucial in buying cltc certification,, so by visiting our web site you can expect the assurance that you are getting the cltc certification, you paid for.

By purchasing through our suggested links you can also rest assured your cltc certification, will be of a high standard. How do we know? Because when we're shopping for cltc certification, ourselves it's where we go.

You might be pondering why we're suggesting you visit outside links rather than stay on our own cltc certification, site. Well it's because we've only recently created our site so it's early days. Our goal is to be the best site for cltc certification, info on the net, and real soon we'll achieve it. So please bookmark us and come back soon.

cltc certification,
laparoscopic instruments
prostate cancer
online reference resources,
md jobs
patient
obgyn
gynecological ultrasound
doctor who
health news
joyce lines
health care
forums,
pharmaceutical marketing
daily medical news

"Orphan Drugs": Hope Where There Is Little or No Hope

 by: Alex Michelini

NEW YORK, N.Y., February 18, 2004 – On a visit to his doctor, Gary Jacob received distressing news – not about himself, but a friend of the doctor's.

While playing with one of his children, the doctor's friend fell and broke a rib. That was bad enough, but during the examination at the hospital, the father was hit with a startling and totally unexpected diagnosis – he had a disease known as multiple myeloma, a bone marrow blood cancer.

The diagnosis was nothing less than a death sentence.

Jacob knew of the anguish of multiple myeloma patients. The disease is incurable and nearly always fatal, one of the rare diseases that have few, if any, available treatments. They are known as "orphan" diseases, shunned by most drug-makers because the patient populations are small and commercial development of a drug is seen as economically unattractive.

Mr. Jacob was aware because, as Chief Executive Officer of Callisto Pharmaceuticals, Inc., a small Manhattan-based biopharmaceutical company, he is leading a scientific effort to develop a new orphan drug called "Atiprimod" for multiple myeloma patients.

"The father's disease brought home to me that what we are doing is really important," says Mr. Jacob. "Everyone agrees we need more drugs to treat multiple myeloma. There are people out there dying without real hope because of a lack of effective treatment for all patients."

In steadily increasing numbers, orphan drugs are providing new doses of hope where little or none at all existed. In the decade before the inception of the federal Food and Drug Administration's orphan drug program, 10 drugs were developed by pharmaceutical companies for orphan diseases. In the decades since, the FDA says nearly 250 new drugs were developed and approved, and hundreds more are in the pipeline.

Atiprimod is one of those wending its way toward the marketplace. Callisto recently obtained orphan drug designation from the FDA, providing the company with financial incentives to continue the costly development process.

The program covers drugs for orphan diseases with patient populations under 200,000.

The National Organization for Rare Disorders reports about 25 million people in the United States suffer from an estimated 6,000 orphan diseases.

Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher's disease, hemophilia and rare forms of cancer were among the orphans without effective medicines until the FDA program went into effect in 1983 and paved the way for new drugs for patients with these diseases.

Large drug-makers have been largely missing from the efforts.

According to the orphan drug program's deputy director, Dr. John McCormick, only 15% of applications for orphan drug designation have come from the larger pharmaceutical companies.

The reason: expectations of unfavorable investment returns.

The FDA orphan drug incentives – grants, seven years of marketing exclusivity and tax breaks – have drawn small pharmaceutical companies with promising drug candidates into the breach.

While the future is brighter, the task is still daunting to develop drugs for orphan diseases.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington's disease also affects about 30,000 patients.

Some diseases affect fewer than 100 patients, according to the National Institutes of Health.

An estimated 50,000 patients have multiple myeloma with 15,000 new patients diagnosed each year. Last year, the FDA approved a new drug Velcade for patients with the disease. However, there are still a number of multiple myeloma patients with no treatment available.

Dr. Kenneth C. Anderson, who played a major role in the preclinical development and clinical trials of Velcade and is now a member of Callisto's Medical Advisory Board, is among the experts who see a need for more drugs to treat multiple myeloma.

"He is excited to see Atiprimod enter clinical trials for evaluation in multiple myeloma patients," Jacob said of Anderson. "He believes it has an opportunity to help patients who have not responded to other drugs. "

Dr. Anderson is director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute in Boston, MA, and Professor of Medicine at Harvard Medical School.

The Phase I/IIa trials for Atiprimod are slated to begin later this month.

Dr. Donald Picker, Callisto's Senior Vice President of Drug Development, said studies of Atiprimod in collaboration with scientists at the National Cancer Institute have been very promising.

"In essence, we've shown in these early studies that Atiprimod has the potential to intervene with cancer cells and tumors in three ways – by inhibiting their formation, by programming their death and by limiting their ability to grow blood vessels necessary for their survival. Taken together, these findings suggest that Atiprimod could potentially represent a novel class of compounds for development for therapeutic intervention in human cancers," said Dr. Picker.

##

About The Author

Alex Michelini is a former award-winning reporter/editor at the New York Daily News. His credits include nomination for a Pulitzer Prize for a series on medical costs. Among his honors, Mr. Michelini received the Deadline Club Award, the Page One Award, the Associated Press Award and the New York Press Club Award (twice). He is the founder of Alex Michelini Public Relations, and has developed and collaborated on articles appearing in the New York Times, the Wall Street Journal, the London Times, the New York Post, the New York Daily News, Bloomberg Radio & TV, CNNfn, WCBS Radio & TV. WINS radio, the Christian Science Monitor, Fox TV, Reuters, Newsday and other media outlets.


michelinialex@aol.com

Google

http://www.gomailings.com/
Fantasy Football Update | Affordable Used Cars | Take It Right | Go Meetings | Medical Meetings On The Net

Take Your Meds   Kids Meet   Doctors On-the-Net